Controlling COVID-19 via test-trace-quarantine.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
20 05 2021
20 05 2021
Historique:
received:
13
02
2021
accepted:
21
04
2021
entrez:
21
5
2021
pubmed:
22
5
2021
medline:
1
6
2021
Statut:
epublish
Résumé
Initial COVID-19 containment in the United States focused on limiting mobility, including school and workplace closures. However, these interventions have had enormous societal and economic costs. Here, we demonstrate the feasibility of an alternative control strategy, test-trace-quarantine: routine testing of primarily symptomatic individuals, tracing and testing their known contacts, and placing their contacts in quarantine. We perform this analysis using Covasim, an open-source agent-based model, which has been calibrated to detailed demographic, mobility, and epidemiological data for the Seattle region from January through June 2020. With current levels of mask use and schools remaining closed, we find that high but achievable levels of testing and tracing are sufficient to maintain epidemic control even under a return to full workplace and community mobility and with low vaccine coverage. The easing of mobility restrictions in June 2020 and subsequent scale-up of testing and tracing programs through September provided real-world validation of our predictions. Although we show that test-trace-quarantine can control the epidemic in both theory and practice, its success is contingent on high testing and tracing rates, high quarantine compliance, relatively short testing and tracing delays, and moderate to high mask use. Thus, in order for test-trace-quarantine to control transmission with a return to high mobility, strong performance in all aspects of the program is required.
Identifiants
pubmed: 34017008
doi: 10.1038/s41467-021-23276-9
pii: 10.1038/s41467-021-23276-9
pmc: PMC8137690
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2993Références
Science. 2020 May 15;368(6492):742-746
pubmed: 32269067
Nat Hum Behav. 2020 Sep;4(9):964-971
pubmed: 32759985
Lancet Child Adolesc Health. 2020 Nov;4(11):817-827
pubmed: 32758453
Nature. 2020 Dec;588(7838):384-387
pubmed: 33318682
Science. 2020 May 8;368(6491):
pubmed: 32234805
Nature. 2020 May;581(7806):15-16
pubmed: 32341558
Wellcome Open Res. 2020 Oct 13;5:239
pubmed: 33154980
PLoS Comput Biol. 2017 Sep 12;13(9):e1005697
pubmed: 28898249
BMJ. 2020 Jun 4;369:m2239
pubmed: 32499391
Lancet Public Health. 2020 Aug;5(8):e452-e459
pubmed: 32682487
Nat Med. 2021 Jan;27(1):94-105
pubmed: 33097835
Nat Med. 2020 May;26(5):672-675
pubmed: 32296168
Nat Commun. 2021 Jan 15;12(1):378
pubmed: 33452267
JAMA Netw Open. 2020 Aug 3;3(8):e2019217
pubmed: 32821920
Lancet Infect Dis. 2020 Oct;20(10):1151-1160
pubmed: 32559451
Lancet Glob Health. 2020 Apr;8(4):e488-e496
pubmed: 32119825
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):451-457
pubmed: 32298245
Nat Commun. 2021 Jan 11;12(1):232
pubmed: 33431829
Nature. 2020 Aug;584(7820):257-261
pubmed: 32512579
Science. 2020 Jun 26;368(6498):1481-1486
pubmed: 32350060
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
N Engl J Med. 2020 May 21;382(21):2005-2011
pubmed: 32220208
Med J Aust. 2020 Oct;213(8):349-351.e1
pubmed: 32981108
Lancet Infect Dis. 2020 May;20(5):533-534
pubmed: 32087114
JAMA. 2020 Jul 7;324(1):25-26
pubmed: 32501504
JAMA Intern Med. 2020 Sep 1;180(9):1156-1163
pubmed: 32356867
Lancet Glob Health. 2021 Apr 12;:
pubmed: 33857499
Lancet Infect Dis. 2020 Oct;20(10):1141-1150
pubmed: 32562601
BMJ. 2020 Dec 9;371:m4777
pubmed: 33298405
JAMA. 2020 Apr 14;323(14):1341-1342
pubmed: 32125371